The small biotech Sotio AS, of Prague, has shunned the limelight since its founding in 2010. Instead of promoting its potential to treat various forms of cancer, the company is letting its technology do the talking.
Sotio's active cellular immunotherapy-multiple antigen presentation (ACI-MAP) platform is the basis for an oncology product pipeline that uses a patient's activated dendritic cells to induce an immune response that targets particular cancer cells.
The technology, called DCVAC, offers the potential to enhance the overall therapeutic effects of standard-of-care treatments. Early trials showed no serious adverse effects or reactions related to DCVAC, which does not appear to increase the toxicity of existing therapies.
In May, the company enrolled the first patient in its global phase III VIABLE (actiVe ImmunotherApy using dendritic cell-Based treatment for Late stage prostatE cancer) study of DCVAC/PCa, an ACI to treat